Morningstar
•
Apr 24, 2026
argenx SE: Argenx Earnings: Vyvgart Sales Drive Operating Profitability, Pipeline Candidates Make Progress
Summary
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular dis
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
May 01, 2026
•
ALNY
APLS: What does Argus have to say about APLS?
Apr 29, 2026
•
APLS
KRYS: Lowering target price to $296.00
Apr 29, 2026
•
KRYS
APLS: What does Argus have to say about APLS?
Apr 22, 2026
•
APLS
KRYS: Raising target price to $300.00
Apr 22, 2026
•
KRYS
